OSDD, besides encouraging the synthesis of novel molecules, also is involved in large scale screening of available databases to identify molecules with   anti-TB and anti-malarial activity. Under this, Indian Institute of Integrative Medicine (CSIR–IIIM) has screened 20,000 drug like molecules to identify potential anti-TB molecules. OSDD runs an open screening facility where researchers can send potent anti-tubercular/anti-malarial compounds for further screening. Under this initiative CSIR-Central Drug Research Institute (CDRI), Lucknow is involved in the biological screening of H37Rv strains and Indian Institute of Chemical Technology (IICT), Hyderabad is involved in screening against Mycobacterium smegmatis strains. Besides screening the molecules submitted in OSDDChem, CSIR-CDRI is also involved in the screening of 37,000 in-house compounds.

So far 2 molecules have been identified as hits and are under hit to lead phase of the drug discovery pipeline. These projects—Thiophene containing tri-substituted methanes CDRI-S006-830 (CSIR-CDRI) and LAMS (CSIR-IGIB and Jubilant Chemsys) are under progress to optimize these molecules.